The ROE as of November 2024 (TTM) for Moleculin Biotech, Inc. (MBRX) is -100.16%

According to Moleculin Biotech, Inc.’s latest financial reports and current stock price. The company's current ROE is -100.16%. This represents a change of 289.87% compared to the average of -25.69% of the last 4 quarters.

Moleculin Biotech, Inc. (MBRX) Historical ROE (quarterly & annually)

How has MBRX ROE performed in the past?

The mean historical ROE of Moleculin Biotech, Inc. over the last ten years is -45.93%. The current -100.16% ROE has changed 118.07% with respect to the historical average. Over the past ten years (40 quarters), MBRX's ROE was at its highest in in the September 2015 quarter at 100.93%. The ROE was at its lowest in in the June 2020 quarter at -64.70%.

Moleculin Biotech, Inc. (MBRX) ROE by Quarter and Year

Discovering the peaks and valleys of Moleculin Biotech, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Moleculin Biotech, Inc. (MBRX) Average ROE

How has MBRX ROE performed in the past?

The current ROE of Moleculin Biotech, Inc. (MBRX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Moleculin Biotech, Inc. (MBRX) ROE vs. Peers

How is MBRX’s ROE compared to its peers?

Moleculin Biotech, Inc.’s ROE is less than Catalyst Biosciences, Inc. (1.20%), greater than Pulmatrix, Inc. (-61.78%), greater than Cyclacel Pharmaceuticals, Inc. (-1873.74%), less than Akari Therapeutics, Plc (1.04%), greater than Onconova Therapeutics, Inc. (-144.95%), greater than Bio-Path Holdings, Inc. (-2842.40%), greater than AN2 Therapeutics, Inc. (-54.72%), greater than Miromatrix Medical Inc. (-119.21%), greater than Inhibikase Therapeutics, Inc. (-194.17%), greater than PMV Pharmaceuticals, Inc. (-21.96%), greater than Anebulo Pharmaceuticals, Inc. (-138.92%), greater than Diffusion Pharmaceuticals Inc. (-55460.19%), greater than Capricor Therapeutics, Inc. (-220.26%), greater than NextCure, Inc. (-57.63%), less than Panbela Therapeutics, Inc. (545.45%), greater than Virax Biolabs Group Limited (-115.10%), greater than Allarity Therapeutics, Inc. (-704.78%), less than ContraFect Corporation (403.13%), greater than Avenue Therapeutics, Inc. (-749.10%),

Build a custom stock screener for Moleculin Biotech, Inc. (MBRX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Moleculin Biotech, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Moleculin Biotech, Inc. (MBRX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Moleculin Biotech, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.